Nanobiotix completes €25m private placement

Nanobiotix had issued the new shares at €15.75 per share via an accelerated bookbuilding offering. The new shares, representing 9.99% of the outstanding company shares prior to the offering. Nanobiotix said it will use the net proceeds from the transaction primarily to drive the development of its lead product NBTXR3, an aqueous suspension of nanoparticles with a special coating designed to penetrate cancer cells and remain within solid tumours.

The first-in-class radio-enhancer currently is being clinically evaluated in soft tissue sarcoma (Phase II/IIIm EU, CAN, Asia), head and neck cancer (Phase I/II, EU), hepatocellular carcinoma and liver metastases (Phase I/II, EU) , prostate cancer (Phase I/II, US) as well as head and neck cancer (Phase I/II) and rectal cancer (Phase I/II) by PharmaEngine. 

Nanobiotix want to push clinical development of NBTXR3 in head and neck cancer to the next step in Europe and the US. The company also wants to prepare market launch of its first-in-class radio-enhancer, which it has filed for in August 2016 in Europe. Furthermore, Nanobiotix wants to progress a preclinical research programme in immuno-oncology with its lead product NBTXR3 kicked-off last year to clinical testing.